Innoviva, Inc. (INVA)

$11.61

-0.25 (-2.11%)
Rating:
Recommendation:
Strong Buy
Symbol INVA
Price $11.61
Beta 0.477
Volume Avg. 0.72M
Market Cap 809.287M
Shares () -
52 Week Range 11.57-20.71
1y Target Est -
DCF Unlevered INVA DCF ->
DCF Levered INVA LDCF ->
ROE 24.99% Buy
ROA 8.75% Neutral
Operating Margin -
Debt / Equity 147.34% Buy
P/E 8.47 Strong Buy
P/B 2.08 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest INVA news


Mr. Michael Aguiar
Healthcare
Biotechnology
NASDAQ Global Select

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.